Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 1 Date: 16 Oct 2021
Reviewer's report:
Page 4. The authors while classifying HDACs should split Class II into Class IIa and Class IIb
HDACs. Moreover, recent  articles should be cited  at reference 8  https://link.springer.com/
chapter/10.1007%2F978-981-15-8179-3_3
Page 4. Due to the important regulation of HDACs in cancer development, HDACs have become
one of the promising anti-cancer targets (no reference is cited). The latest reference https://
link.springer.com/chapter/10.1007%2F978-981-15-8179-3_4
Page 4. Due to the non-specific toxicity of pan-HDAC inhibitors, development of
isoform-selective HDAC inhibitors has become the main direction for HDACI. No
reference is cited. Add the latest reference with relevant content https://link.springer.com/
chapter/10.1007%2F978-981-15-8179-3_4
The authors have mentioned 0 what does this mean. It is not mentioned what were solvent
controls. As HDAC inhibitors come in solid form and need to be reconstituted in solvents in
which they dissolve. Thus authors should clearly mention solvent controls. Further either higher
end solvent control should be used or for each concentration separate solvent control should
be used.
Again in Figure 2, the authors have mentioned control. Clearly mention what is control. What
treatment has been given to control. Otherwise the experiments are not reliable at all.
In all cases 0 and control has been mentioned what is this control is not clear. Untill the authors
will not mention clearly what is this control, the results are highly doubtful.
Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 1 Date: 16 Oct 2021
Reviewer's report:
Page 4. The authors while classifying HDACs should split Class II into Class IIa and Class IIb
HDACs. Moreover, recent  articles should be cited  at reference 8  https://link.springer.com/
chapter/10.1007%2F978-981-15-8179-3_3
Page 4. Due to the important regulation of HDACs in cancer development, HDACs have become
one of the promising anti-cancer targets (no reference is cited). The latest reference https://
link.springer.com/chapter/10.1007%2F978-981-15-8179-3_4
Page 4. Due to the non-specific toxicity of pan-HDAC inhibitors, development of
isoform-selective HDAC inhibitors has become the main direction for HDACI. No
reference is cited. Add the latest reference with relevant content https://link.springer.com/
chapter/10.1007%2F978-981-15-8179-3_4
The authors have mentioned 0 what does this mean. It is not mentioned what were solvent
controls. As HDAC inhibitors come in solid form and need to be reconstituted in solvents in
which they dissolve. Thus authors should clearly mention solvent controls. Further either higher
end solvent control should be used or for each concentration separate solvent control should
be used.
Again in Figure 2, the authors have mentioned control. Clearly mention what is control. What
treatment has been given to control. Otherwise the experiments are not reliable at all.
In all cases 0 and control has been mentioned what is this control is not clear. Untill the authors
will not mention clearly what is this control, the results are highly doubtful.
Please review this paper.
user
Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 1 Date: 16 Oct 2021
Reviewer's report:
Page 4. The authors while classifying HDACs should split Class II into Class IIa and Class IIb
HDACs. Moreover, recent  articles should be cited  at reference 8  https://link.springer.com/
chapter/10.1007%2F978-981-15-8179-3_3
Page 4. Due to the important regulation of HDACs in cancer development, HDACs have become
one of the promising anti-cancer targets (no reference is cited). The latest reference https://
link.springer.com/chapter/10.1007%2F978-981-15-8179-3_4
Page 4. Due to the non-specific toxicity of pan-HDAC inhibitors, development of
isoform-selective HDAC inhibitors has become the main direction for HDACI. No
reference is cited. Add the latest reference with relevant content https://link.springer.com/
chapter/10.1007%2F978-981-15-8179-3_4
The authors have mentioned 0 what does this mean. It is not mentioned what were solvent
controls. As HDAC inhibitors come in solid form and need to be reconstituted in solvents in
which they dissolve. Thus authors should clearly mention solvent controls. Further either higher
end solvent control should be used or for each concentration separate solvent control should
be used.
Again in Figure 2, the authors have mentioned control. Clearly mention what is control. What
treatment has been given to control. Otherwise the experiments are not reliable at all.
In all cases 0 and control has been mentioned what is this control is not clear. Untill the authors
will not mention clearly what is this control, the results are highly doubtful.
assistant